The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE
Open accessAbstract
Taken orally, the drug dimethyl fumarate (DMF) has been shown to improve functional outcomes for patients with MS; however, it is unclear how DMF mediates a protective effect. DMF and, more so, its active metabolite, monomethyl fumarate, are known agonists of the hydroxycarboxylic acid receptor 2 (HCA₂), a G protein-coupled membrane receptor. Here, we evaluated the contribution of HCA₂ in mediating the protective effect afforded by DMF in EAE, a mouse model of MS. DMF treatment reduced neurological deficit, immune cell infiltration, and demyelination of the spinal cords in wild-type mice, but not in Hca2⁻/⁻ mice, indicating that HCA₂ is required for the therapeutic effect of DMF. In particular, DMF decreased the number of infiltrating neutrophils in a HCA₂-dependent manner, likely by interfering with neutrophil adhesion to endothelial cells and chemotaxis. Together, our data indicate that HCA₂ mediates the therapeutic effects of DMF in EAE. Furthermore, identification of HCA₂ as a molecular target may help to optimize MS therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neutrophil recruitment and function in health and inflammation
Kolaczkowska, E., & Kubes, P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3399 · Cited by 5,472
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155
Innate immunity in the central nervous system
Ransohoff, R. M., & Brown, M. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58644 · Cited by 1,034
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K., & Offermanns, S. (2003) · Nature Medicine · doi:10.1038/nm824 · Cited by 791
Self-citationFumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
Ghoreschi, K., Brück, J., Kellerer, C., Deng, C., Peng, H., Rothfuss, O., Hussain, R. Z., Gocke, A. R., Respa, A., Glocova, I., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100977 · Cited by 352
Carlson, T., Kroenke, M., Rao, P., Lane, T. E., & Segal, B. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072404 · Cited by 272
Schilling, S., Goelz, S., Linker, R., Luehder, F., & Gold, R. (2006) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2006.03094.x · Cited by 271
β-Arrestin1 mediates nicotinic acid–induced flushing, but not its antilipolytic effect, in mice
Walters, R. W., Shukla, A. K., Kovacs, J. J., Violin, J. D., DeWire, S. M., Lam, C. M., Chen, J. R., Muehlbauer, M. J., Whalen, E. J., & Lefkowitz, R. J. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36806 · Cited by 240
Neutrophils in multiple sclerosis are characterized by a primed phenotype
Naegele, M., Tillack, K., Reinhardt, S., Schippling, S., Martin, R., & Sospedra, M. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.11.009 · Cited by 235
Offermanns, S., Colletti, S. L., Lovenberg, T. W., Semple, G., Wise, A., & IJzerman, A. P. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003301 · Cited by 200
Self-citationHanson, J., Gille, A., Zwykiel, S., Lukasova, M., Clausen, B. E., Ahmed, K., Tunaru, S., Wirth, A., & Offermanns, S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42273 · Cited by 197
Self-citationLangerhans Cells Release Prostaglandin D2 in Response to Nicotinic Acid
Maciejewski-Lenoir, D., Richman, J. G., Hakak, Y., Gaidarov, I., Behan, D. P., & Connolly, D. T. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700586 · Cited by 188
Mouse models for multiple sclerosis: Historical facts and future implications
Croxford, A. L., Kurschus, F. C., & Waisman, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.010 · Cited by 181
Murikinati, S. R., Jüttler, E., Keinert, T., Ridder, D. A., Muhammad, S., Waibler, Z., Ledent, C. A., Zimmer, A., Kalinke, U., & Schwaninger, M. (2009) · The FASEB Journal · doi:10.1096/fj.09-141275 · Cited by 157
Self-citationMcColl, S. R., Staykova, M. A., Wozniak, A., Fordham, S., Bruce, J., & Willenborg, D. O. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.11.6421 · Cited by 142
The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist
Tang, H. L., Lu, J. Y.-L., Zheng, X., et al. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.041 · Cited by 125
Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A)
Kostylina, G., Simon, D., Fey, M. F., Yousefi, S., & Simon, H. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402238 · Cited by 119
Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials
Lukasova, M., Hanson, J., Tunaru, S., & Offermanns, S. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.08.002 · Cited by 112
Self-citationMyelin Repair Is Accelerated by Inactivating CXCR2 on Nonhematopoietic Cells
Liu, L., Darnall, L., Hu, T., Choi, K., Lane, T. E., & Ransohoff, R. M. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1238-10.2010 · Cited by 89
Määttä, J. A., Sjöholm, U. R., Nygårdas, P., Salmi, A. A., & Hinkkanen, A. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00135-0 · Cited by 44
Zhang, J., Chen, J., Li, Y., Cui, X., Zheng, X., Roberts, C. J., Lü, M., Elias, S. B., & Chopp, M. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.07.011 · Cited by 32
Dimethyl fumarate: a Janus-faced substance?
Kees, F. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.804912 · Cited by 26
High-Affinity Niacin Receptor GPR109A Agonists
Shen, H. C., & Colletti, S. L. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45005-8 · Cited by 7
Cited by
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases
Sun, M., Wu, W., Liu, Z., & Cong, Y. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-016-1242-9 · Cited by 1,047
The neuropharmacology of butyrate: the bread and butter of the microbiota-gut-brain axis
Stilling, R. M., van de Wouw, M., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.06.011 · Cited by 891
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
GPCR-Mediated Signaling of Metabolites
Husted, A. S., Trauelsen, M., Rudenko, O., Hjorth, S. A., & Schwartz, T. W. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.03.008 · Cited by 590
Metadata
- Authors
- Chen, H., Assmann, J. C., Krenz, A., Rahman, M., Grimm, M., Karsten, C. M., Köhl, J., Offermanns, S., Wettschureck, N., & Schwaninger, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-04-01
- Volume
- 124
- Issue
- 5
- Pages
- 2188-2192
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1972403093
- Cited by
- 297
- References
- 25
- FWCI
- 20.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.